Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Upcoming Meetings: FDA device "grassroots" meetings

This article was originally published in The Gray Sheet

Executive Summary

FDA device "grassroots" meetings: FDA's final quality system rule and preannounced inspection pilot program will be among topics discussed at three Southeast region "grassroots" meetings scheduled to take place in Atlanta; Charlotte, North Carolina; and Orlando, Florida on Nov. 7, Dec. 11, and Jan. 14, respectively. The forums, organized in conjunction with the Health Industry Manufacturers Association and the Biomedical Exchange of the Greater Miami Chamber of Commerce, will feature presentations by district and regional agency representatives. For information on the Atlanta or Charlotte meetings, contact FDA's Sheila Bayne-Lisby at 404/347-4001, ext. 5231; for information on the Orlando meeting, contact FDA's Frank Goodwin at 407-648-6997, ext. 221...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel